Navigation Links
Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
Date:4/10/2008

EXTON, Pa., April 10 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that it will release its earnings results for its third quarter ended March 31, 2008 at 7:00 A.M. Eastern Time on Tuesday, April 29, 2008.

Joe Kaufmann, President and CEO, will be hosting a teleconference discussing the earnings results on Tuesday, April 29, 2008 at 9:00 A.M. Eastern Time.

To participate in the teleconference call, dial 1-612-234-9959. The teleconference call will also be available for replay starting Tuesday, April 29, 2008 at 11:00 A.M. Eastern Time through Tuesday, May 6, 2008 at 11:59 A.M. Eastern Time by dialing 1-800-475-6701 with an access code of 918341.

Individuals interested in listening to the teleconference may also do so over the Internet at http://www.kenseynash.com. To listen to the live teleconference call, please go to the http://www.kenseynash.com website and choose the Investor Relations page. Please allow 15 minutes prior to the start of the call to register and download and/or install any necessary software. A replay of the teleconference will be archived on the http://www.kenseynash.com website and may be accessed following the teleconference.

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily in the endovascular, sports medicine and spine markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. Kensey Nash has also commercialized a series of innovative products through its own direct endovascular sales force. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
2. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
3. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
6. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. BioElectronics Corporation Announces Singapore and Malaysia Sales
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. ... Disease drug candidate, code-named "KM-819." KM-819 is an orally active small molecule ... in South Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study ...
(Date:12/20/2018)... ... , ... New Year’s brings reflection and desire to improve for individuals and ... (EU) on the horizon, Jim Kasic, president and CEO of Boulder iQ, suggests five ... Device Regulation (MDR), digital health, and big data are just a few of the ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial ... (human) ingredient. This has been part of their strategic plan and an important ... certification creates custom fermentation opportunities for MDG within the $44 Billion human probiotic ...
Breaking Biology Technology:
(Date:1/4/2019)... ... January 03, 2019 , ... Over the last ... their drug discovery research workflows with biology ranging from single cell-type spheroids to ... in vitro studies, they create several challenges that need to be overcome in ...
(Date:12/25/2018)... , ... December 24, 2018 , ... ... The Rockefeller University have discovered a new use for a long-standing computational concept ... spam control, blocking unwanted files and messages. Using blacklisting as a filter to ...
(Date:12/19/2018)... ... , ... InTouchMD’s flagship product, Pulse , has been honored by PM360 ... is featuring the recognition in its 7th annual Innovations issue, created for purpose of ... medical device industries. , “This recognition comes at an exciting time for Pulse as ...
Breaking Biology News(10 mins):